Clinical Trial Update: OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck. [Phase 4]

View source ↗

Summary

Phase 4 bioequivalence study of OXEMET 1000 mg coated tablets (metformin hydrochloride) with GLAFORNIL; completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• OXEMET 1000 mg coated tablets (metformin hydrochloride) (metformin hydrochloride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2017-12-22